JP2007537289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007537289A5 JP2007537289A5 JP2007513391A JP2007513391A JP2007537289A5 JP 2007537289 A5 JP2007537289 A5 JP 2007537289A5 JP 2007513391 A JP2007513391 A JP 2007513391A JP 2007513391 A JP2007513391 A JP 2007513391A JP 2007537289 A5 JP2007537289 A5 JP 2007537289A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halo
- disease
- substituted
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 7
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000030533 eye disease Diseases 0.000 claims description 4
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 208000023504 respiratory system disease Diseases 0.000 claims description 4
- 208000017520 skin disease Diseases 0.000 claims description 4
- 208000019553 vascular disease Diseases 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- 230000036523 atherogenesis Effects 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000001475 halogen functional group Chemical group 0.000 claims 9
- -1 benzo [b] furanyl Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000002947 alkylene group Chemical group 0.000 claims 7
- 208000002705 Glucose Intolerance Diseases 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 201000009104 prediabetes syndrome Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 210000003205 muscle Anatomy 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 2
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 108010015181 PPAR delta Proteins 0.000 claims 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 2
- 235000010290 biphenyl Nutrition 0.000 claims 2
- 239000004305 biphenyl Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 230000004153 glucose metabolism Effects 0.000 claims 2
- 230000002641 glycemic effect Effects 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000006410 propenylene group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000003577 HIV wasting syndrome Diseases 0.000 claims 1
- 229940083324 Selective androgen receptor modulator Drugs 0.000 claims 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims 1
- 229940122388 Thrombin inhibitor Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 229940125710 antiobesity agent Drugs 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 235000021407 appetite control Nutrition 0.000 claims 1
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 230000001906 cholesterol absorption Effects 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004220 muscle function Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229960003604 testosterone Drugs 0.000 claims 1
- 239000003868 thrombin inhibitor Substances 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 5
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 5
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- CAOUTCDDAKSUJP-UHFFFAOYSA-N methyl 2-(4-acetyl-2-methylphenoxy)acetate Chemical compound COC(=O)COC1=CC=C(C(C)=O)C=C1C CAOUTCDDAKSUJP-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57100404P | 2004-05-14 | 2004-05-14 | |
| PCT/US2005/016747 WO2005113506A1 (en) | 2004-05-14 | 2005-05-13 | Compounds and compositions as ppar modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007537289A JP2007537289A (ja) | 2007-12-20 |
| JP2007537289A5 true JP2007537289A5 (https=) | 2008-02-07 |
Family
ID=35428365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007513391A Pending JP2007537289A (ja) | 2004-05-14 | 2005-05-13 | Ｐｐａｒモジュレーターとしての化合物および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7745445B2 (https=) |
| EP (1) | EP1756062A4 (https=) |
| JP (1) | JP2007537289A (https=) |
| KR (1) | KR20070026503A (https=) |
| CN (1) | CN1980894A (https=) |
| AU (1) | AU2005245418B2 (https=) |
| BR (1) | BRPI0510024A (https=) |
| CA (1) | CA2564365A1 (https=) |
| MX (1) | MXPA06013195A (https=) |
| RU (1) | RU2006144121A (https=) |
| WO (1) | WO2005113506A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005024384D1 (de) | 2004-05-05 | 2010-12-09 | High Point Pharmaceuticals Llc | Neue verbindungen, ihre herstellung und verwendung |
| WO2010127205A2 (en) * | 2009-04-30 | 2010-11-04 | Dr. Reddy's Laboratories Ltd. | Fixed dose drug combination formulations |
| ES2372617T3 (es) | 2005-06-30 | 2012-01-24 | High Point Pharmaceuticals, Llc | Ácidos fenoxiacéticos como activadores de ppar-delta. |
| US20090156579A1 (en) * | 2005-10-25 | 2009-06-18 | Hasegawa Philip A | Combination of a Dipeptidyl Peptidase-4 Inhibitor and an Anti-Hypertensive Agent for the Treatment of Diabetes and Hypertension |
| US20070116756A1 (en) * | 2005-11-23 | 2007-05-24 | Dr. Reddy's Laboratories Limited | Stable pharmaceutical compositions |
| CA2640520C (en) * | 2006-03-02 | 2014-04-22 | Warner Chilcott Company, Inc. | Extended cycle multiphasic oral contraceptive method |
| US7943612B2 (en) | 2006-03-09 | 2011-05-17 | High Point Pharmaceuticals, Llc | Compounds that modulate PPAR activity, their preparation and use |
| CA2672420A1 (en) * | 2006-12-29 | 2008-07-10 | The Salk Institute For Biological Studies | Methods for enhancing exercise performance |
| US8080658B2 (en) * | 2007-07-10 | 2011-12-20 | Idemitsu Kosan Co., Ltd. | Material for organic electroluminescent element and organic electroluminescent element employing the same |
| JP5291708B2 (ja) * | 2007-07-25 | 2013-09-18 | 中国人民解放軍軍事医学科学院毒物薬物研究所 | アリールピリミジン誘導体、その製造方法、及び、その使用 |
| US20090163481A1 (en) * | 2007-12-13 | 2009-06-25 | Murphy Brian J | Ppar-delta ligands and methods of their use |
| WO2009143183A1 (en) * | 2008-05-19 | 2009-11-26 | University Of Tennessee Research Foundation, The | Pyrimidine non-classical cannabinoid compounds and related methods of use |
| EP2533641B1 (de) | 2010-02-09 | 2016-07-13 | Bayer CropScience AG | Hydrazin-substituierte anthranilsäurederivate |
| KR20130087495A (ko) | 2010-06-15 | 2013-08-06 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 안트라닐산 유도체 |
| RU2013114390A (ru) | 2010-08-31 | 2014-10-10 | СНУ Ар энд ДиБи ФАУНДЕЙШН | Применение фетального репрограммирования посредством ppar-дельта-агониста |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| TWI683808B (zh) * | 2017-07-18 | 2020-02-01 | 德商菲尼克斯 Ｆｘｒ有限責任公司 | 含有胺或(硫)醯胺之lxr調節劑 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2665159B1 (fr) * | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| JPH08333287A (ja) * | 1995-06-02 | 1996-12-17 | Fuji Yakuhin Kogyo Kk | 芳香環置換アルキルカルボン酸及びアルカノール誘導体とそれらを含有する抗血栓剤 |
| AU2831901A (en) * | 2000-01-28 | 2001-08-07 | Novo Nordisk A/S | Propionic acid derivatives and their use in the treatment of diabetes and obesity |
| US6555577B1 (en) * | 2000-01-28 | 2003-04-29 | Novo Nordisk A/S | Compounds, their preparation and use |
| WO2002076438A2 (en) * | 2001-03-23 | 2002-10-03 | Chugai Seiyaku Kabushiki Kaisha | Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis |
| US6875780B2 (en) * | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
| AU2003273783C1 (en) * | 2002-10-28 | 2010-08-12 | Vtv Therapeutics Llc | Novel compounds and their use as PPAR-modulators |
| DE602005024384D1 (de) * | 2004-05-05 | 2010-12-09 | High Point Pharmaceuticals Llc | Neue verbindungen, ihre herstellung und verwendung |
-
2005
- 2005-05-13 BR BRPI0510024-0A patent/BRPI0510024A/pt not_active IP Right Cessation
- 2005-05-13 RU RU2006144121/04A patent/RU2006144121A/ru not_active Application Discontinuation
- 2005-05-13 CA CA002564365A patent/CA2564365A1/en not_active Abandoned
- 2005-05-13 US US11/596,598 patent/US7745445B2/en not_active Expired - Fee Related
- 2005-05-13 CN CNA2005800196459A patent/CN1980894A/zh active Pending
- 2005-05-13 AU AU2005245418A patent/AU2005245418B2/en not_active Ceased
- 2005-05-13 KR KR1020067023755A patent/KR20070026503A/ko not_active Withdrawn
- 2005-05-13 JP JP2007513391A patent/JP2007537289A/ja active Pending
- 2005-05-13 EP EP05751010A patent/EP1756062A4/en not_active Withdrawn
- 2005-05-13 WO PCT/US2005/016747 patent/WO2005113506A1/en not_active Ceased
- 2005-05-13 MX MXPA06013195A patent/MXPA06013195A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007537289A5 (https=) | ||
| TWI376370B (en) | Compounds for inflammation and immune-related uses | |
| CN101616915B (zh) | 调控激酶级联的组合物以及方法 | |
| JP2008513516A5 (https=) | ||
| TWI244471B (en) | Therapeutic biaryl derivatives | |
| JP5115474B2 (ja) | 消化管潰瘍治療又は予防薬 | |
| JP5043105B2 (ja) | 有機化合物 | |
| CN1379766A (zh) | 治疗糖尿病的苯甲酸衍生物 | |
| US9737522B2 (en) | NMDA receptor modulators and uses related thereto | |
| JP6238460B2 (ja) | 脂質異常症治療剤 | |
| TW200848026A (en) | Dihydroindazole compounds useful in treating iron disorders | |
| TWI691475B (zh) | Ｕｒａｔ１抑制劑 | |
| RU2006105717A (ru) | Производные пиперазина и их применение в качестве терапевтических агентов | |
| JP2016500063A5 (https=) | ||
| CA2858787A1 (en) | Prodrugs of tertiary amine compounds | |
| TW200843733A (en) | Biaryl and biheteroaryl compounds useful in treating iron disorders | |
| EP3210969B1 (en) | Kcnq2-5 channel activator | |
| RU2746602C2 (ru) | Агонисты ppar, соединения, фармацевтические композиции и способы их применения | |
| TW200405812A (en) | Compounds that modulate PPAR activity | |
| CN105315224A (zh) | 环戊基丙烯酰胺衍生物 | |
| RU2001120723A (ru) | Производные имидазола и их медицинское применение | |
| US20210017149A1 (en) | GluN2C/D Subunit Selective Antagonists of the N-Methyl-D-Aspartate Receptor | |
| JP2007531764A5 (https=) | ||
| US11319296B2 (en) | DP antagonist | |
| JP2007522178A5 (https=) |